RT Journal Article SR Electronic T1 Molecular Imaging of Biomarkers in Breast Cancer JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 53S OP 59S DO 10.2967/jnumed.115.157909 VO 57 IS Supplement 1 A1 Gary A. Ulaner A1 Chris C. Riedl A1 Maura N. Dickler A1 Komal Jhaveri A1 Neeta Pandit-Taskar A1 Wolfgang Weber YR 2016 UL http://jnm.snmjournals.org/content/57/Supplement_1/53S.abstract AB The success of breast cancer therapy is ultimately defined by clinical endpoints such as survival. It is valuable to have biomarkers that can predict the most efficacious therapies or measure response to therapy early in the course of treatment. Molecular imaging has a promising role in complementing and overcoming some of the limitations of traditional biomarkers by providing the ability to perform noninvasive, repeatable whole-body assessments. The potential advantages of imaging biomarkers are obvious and initial clinical studies have been promising, but proof of clinical utility still requires prospective multicenter clinical trials.